MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

George Evans had the opportunity of a lifetime as he stepped up to the mound to throw the first pitch at the Athletics game against the Houston Astros ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, if any, might work best.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced ...

With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...